228 results about "ECT therapy" patented technology

An image guided navigation system for navigating a region of a patient which is gated using ECG signals to confirm diastole. The navigation system includes an imaging device, a tracking device, a controller, and a display. The imaging device generates images of the region of a patient. The tracking device tracks the location of the instrument in a region of the patient. The controller superimposes an icon representative of the instrument onto the images generated from the imaging device based upon the location of the instrument. The display displays the image with the superimposed instrument. The images and a registration process may be synchronized to a physiological event.

The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

Systems and methods for introducing one or more stimulating drugs and / or applying electrical stimulation to tissue affecting the penis to treat erectile dysfunction (for instance, following prostate surgery) uses at least one implantable system control unit (SCU) producing electrical pulses delivered via electrodes and / or producing drug infusion pulses, wherein the stimulating drug(s) are delivered via one or more pumps and infusion outlets.

A combination therapy for treating depressive disorders is provided herein. The combination therapy comprises administering an effective amount of bupropion or its metabolites together with at least one serotonin 5-HT1A partial agonist or its metabolites to a patient in need of treatment of the depressive disorder. Pharmaceutical formulations, including packaged pharmaceutical formulations, comprising this combination are also provided herein.

The invention provides methods and combination therapies for treating and / or preventing and / or slowing the onset and / or development of Alzheimer's disease using a hydrogenated pyrido (4,3-b) indole (e.g., dimebon) in conjunction with another compound, pharmaceutically acceptable salt thereof or therapy for Alzheimer's disease.

A neural stimulation therapy system for atherosclerotic plaques is provided. One aspect of this disclosure relates to a medical device for applying neural stimulation therapy for atherosclerotic plaques. The device includes a neural stimulator adapted to deliver an electrical signal through at least one electrode to an autonomic neural target. The device also includes a controller to control the neural stimulator to provide a therapy for atherosclerotic plaques. The device is external to a human body in an embodiment, and includes an implantable medical device (IMD) in various embodiments. According to an embodiment, the device includes a neural stimulation lead connected to the neural stimulator. The neural stimulator delivers electrical signals with waveform parameters based on sensed arterial blockage levels, according to various embodiments. Other aspects and embodiments are provided herein.

An implantable neurostimulator system for treating psychiatric disorders includes scheduled and responsive therapy capabilities including responsive stimulation applied to the cingulate gyrus of the brain. Methods for treating depression, bipolar disorder, anxiety and obsessive-compulsive disorders, post-traumatic stress disorder, addiction, schizophrenia, and autism and other developmental disorders employ an inventive system to advantageously reduce symptoms and address underlying causes of the disorders.

A neurological motor therapy suit includes a vest which is snugly, but removably, secured around the shoulders and chest of a patient. The vest completely encircles a portion of the upper torso of the patient and is constructed of a substantially non-elastic material. A pant garment is detachably secured to the patient so that the pant garment extends around both the hips of the patient as well as the upper portion of each thigh. The pant garment is also constructed of a substantially non-elastic material. A plurality of the elastic bands extend between and interconnect the vest and the pant garment. Optionally, the therapy suit includes a cap removably secured to the head of the patient, knee supports removably secured to the knees of the patient, and / or shoe supports. Elastic bands extend between the cap, knee support and shoe supports to other parts of the therapy suit.

Systems and methods for introducing one or more stimulating drugs and / or applying electrical stimulation to tissue affecting the penis to treat erectile dysfunction (for instance, following prostate surgery) uses at least one implantable system control unit (SCU) producing electrical pulses delivered via electrodes and / or producing drug infusion pulses, wherein the stimulating drug(s) are delivered via one or more pumps and infusion outlets.

A continuous renal replacement therapy (CRRT) device adapted to be worn on a portion of the body of a patient. The CRRT device is worn by the patient and operates on rechargeable batteries for more than 5 hours dialysate is used to remove impurities from the blood. The dialysate is recycled and refreshed by a filter section. Less than one liter of dialysate is required to circulate through the wearable CRRT device.

A neurological motor therapy suit includes a vest which is snugly, but removably, secured around the shoulders and chest of a patient. The vest completely encircles a portion of the upper torso of the patient and is constructed of a substantially non-elastic material. A pant garment is detachably secured to the patient so that the pant garment extends around both the hips of the patient as well as the upper portion of each thigh. The pant garment is also constructed of a substantially non-elastic material. A plurality of the elastic bands extend between and interconnect the vest and the pant garment. Optionally, the therapy suit includes a cap removably secured to the head of the patient, knee supports removably secured to the knees of the patient, and / or shoe supports. Elastic bands extend between the cap, knee support and shoe supports to other parts of the therapy suit.

A radiation therapy treatment system and method of treating a patient with radiation. The system integrates positioning of the patient, treatment planning, and delivery of the plan. As a result of the integration of imaging capabilities into the treatment apparatus, and efficient processes for contouring and planning, a patient can be treated in approximately 20 minutes or less. The method includes acquiring image data from the patient, defining a target region with one or more predefined shapes, generating a treatment plan based on the defined target region, and delivering radiation to the target region.

This application provides methods of improving gene therapy by combining gene therapy with active site-specific chaperones (ASSCs). The ASSC increases the stability and efficiency of the protein encoded by the recombinant gene that is administered.

The present invention relates to photosensitizer immunoconjugate compositions and combination therapies for use in cancer related photodynamic treatments and diagnostic methods. Photosensitizer immunoconjugates comprising a photosensitizer conjugated to a tumor-specific and / or tumoricidial antibody and processes for the preparation thereof are described. The use of photosensitizer immunoconjugates (PICs) offers improved photosensitizer delivery specificity for diagnostic and therapeutic applications. Combination therapies to co-localize activated photosensitizer compounds and tumoricidal antibodies in tumor tissues are also described.

The present invention relates to compositions comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

The present invention is drawn to methods and compounds for transcutaneous photodynamic therapy ("PDT") of a target tissue or compositions in a mammalian subject, which includes administering to the subject a therapeutically effective amount of a photosensitizing agent or a photosensitizing agent delivery system or a prodrug where the photosensitizing agent or photosensitizing agent delivery system or prodrug selectively binds to the target tissue; and irradiating at least a portion of the subject with light at a wavelength absorbed by the photosensitizing agent or if prodrug, by a prodrug product thereof where the light is provided by a light source, and where the irradiation is at low fluence rate that results in the activation of the photosensitizing agent or prodrug product. These methods of transcutaneous PDT are useful in the treatment of specifically selected target tissues, such as: vascular endothelial tissue abnormal vascular wall of tumors; tumors of the head and neck; tumors of the gastrointestinal tract; tumors of the liver; tumors of the esophopharyngeal; tumors of the lung; lymphoid tissue; lesions in the vascular system; hone marrow and tissue related to autoimmune disease.

An implantable stimulator(s) with at least one infusion outlet and / or at least one electrode, is implanted with the outlet(s) and / or electrode(s) located adjacent to a pudendal nerve(s) and potentially other nerve(s) innervating the reproductive organs, such as the cavernous nerve(s). Stimulation of such nerve(s) is provided via stimulating drugs and / or electrical stimulation as a therapy for erectile dysfunction. The stimulator uses a power source / storage device, such as a rechargeable battery. Periodic recharging of such a battery is accomplished, for example, by inductive coupling with an external appliance. The stimulator provides means of stimulating a nerve(s) when desired, without the need for external appliances during the stimulation session. When necessary, external appliances are used for the transmission of data to and / or from the stimulator(s) and for the transmission of power. The system is capable of open- and closed-loop operation. In closed-loop operation, at least one implant includes a sensor, and the sensed condition is used to adjust stimulation parameters.

Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue and results in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and scatter threshold laser coagulation therapy surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Threshold laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.

A method is provided that includes identifying that a subject is at risk of suffering from vascular dementia (VaD). Responsively to the identifying, a risk of development of the VaD is reduced by applying electrical stimulation to a site of the subject selected from the group consisting of: a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve; and configuring the stimulation to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow of the subject, and a release of one or more neuroprotective substances. Other embodiments are also described.

Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X- rays and / or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and / or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and / or one or more chemotherapeutic agent.

The present invention relates to methods for the stratification of a multiple myeloma (MM) patient comprising determining whether or not B-cells, preferably malignant B-cells of said patient express BCMA protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (MM) therapy is based on whether or not BCMA is expressed on the cell surface of B-cells, preferably malignant B-cells of a patient. Furthermore, antibody-based therapies for patients who have BCMA positive malignant B-cells are provided.

The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.

The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.

A neurological motor therapy suit includes a vest which is snugly, but removably, secured around the shoulders and chest of a patient. The vest completely encircles a portion of the upper torso of the patient and is constructed of a substantially non-elastic material. A pant garment is detachably secured to the patient so that the pant garment extends around both the hips of the patient as well as the upper portion of each thigh. The pant garment is also constructed of a substantially non-elastic material. A plurality of the elastic bands extend between and interconnect the vest and the pant garment. An elbow support is removably secured to the patient's elbow while a hand support is removably secured to the patient's hand. Both the elbow support and hand support include a plurality of hooks so that elastic bands detachably secure the hooks on the elbow support and hand support together as well as between the vest and the elbow support.

The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.

The present invention provides improved methods, kits, and pharmaceutical compositions for increasing hematopoietic cell survival and / or reducing or preventing the side effects of chemotherapy, and mobilizing hematopoietic progenitor cells from bone marrow into peripheral blood following chemotherapy, comprising administering an effective amount angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II (AII) AII analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists to a patient in need of chemotherapy.

The present invention provides methods of detection, including early detection, for cancer or other diseases and normal physiologic processes mediated by global epigenetic changes, by using one or more of the following biomarkers: a global DNA methylation index, a global histone H4 acetylation index, and a global histone H4 trimethylation index. These methods are useful for, among other things, assessing the effectiveness of treatment, monitoring relapse, and clinical staging of cancer and other chronic as well as acute diseases. These methods are also useful for among other things monitoring the effectiveness of strategies and therapies used to modify lifestyle and contextual effects to prevent disease, foster wellness and enable health promotion.

A method is provided that includes identifying that a subject is at risk of suffering from vascular dementia (VaD). Responsively to the identifying, a risk of development of the VaD is reduced by applying electrical stimulation to a site of the subject selected from the group consisting of: a sphenopalatine ganglion (SPG), a greater palatine nerve, a lesser palatine nerve, a sphenopalatine nerve, a communicating branch between a maxillary nerve and an SPG, an otic ganglion, an afferent fiber going into the otic ganglion, an efferent fiber going out of the otic ganglion, an infraorbital nerve, a vidian nerve, a greater superficial petrosal nerve, and a lesser deep petrosal nerve; and configuring the stimulation to induce at least one neuroprotective occurrence selected from the group consisting of: an increase in cerebral blood flow of the subject, and a release of one or more neuroprotective substances. Other embodiments are also described.